Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
| Autor: | Faeze Sabet, Narges Valizade, Samane Sadat Hosseiny, Mohammad Mehdi Etemadi, Ali Shoeibi, Rosita Vakili, Reza Boostani, Bahare Fazeli, Seyed Abdolrahim Rezaee |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Gene Expression Regulation Viral Male medicine.medical_specialty Prednisolone Anti-Inflammatory Agents Retroviridae Proteins Frequent urination Peripheral blood mononuclear cell Gastroenterology Myelopathy Disability Evaluation Young Adult Pegylated interferon Internal medicine Tropical spastic paraparesis medicine Humans Pharmacology (medical) Spasticity RNA Messenger Pharmacology business.industry Gene Products tax Middle Aged medicine.disease Paraparesis Tropical Spastic Leukemia Basic-Leucine Zipper Transcription Factors Cross-Sectional Studies Immunology Leukocytes Mononuclear Female Original Article Neurology (clinical) Interferons medicine.symptom Vanadates business medicine.drug |
| Zdroj: | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 12(4) |
| ISSN: | 1878-7479 |
| Popis: | Considering that there is no effective treatment for human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis, this study aimed to assess the impact of triple combination therapy—interferon-α, valproic acid, and prednisolone—on clinical outcomes, main HTLV-1 viral factors, and host anti-HTLV-1 antibody response. HTLV-1 proviral load (PVL), and HBZ and Tax mRNA expression levels were measured in peripheral blood mononuclear cells of 13 patients with HTLV-1-associated myelopathy/tropical spastic paraparesis before and after treatment with 180 μg pegylated interferon once a week, 10–20 mg/kg/day sodium valproate, and 5 mg/day prednisolone for 25 weeks using a TaqMan real-time polymerase chain reaction assay. Furthermore, anti-HTLV-1 titer, Osame Motor Disability Score, Ashworth spasticity scale, and urinary symptoms (through standard questionnaire and clinical monitoring) were assessed in patients before and after the treatment. HTLV-1 PVL and HBZ expression significantly decreased after the treatment [PVL from 1443 ± 282 to 660 ± 137 copies/104 peripheral blood mononuclear cells (p = 0.01); and HBZ from 8.0 ± 1.5 to 3.0 ± 0.66 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink